Morgan Stanley assumed coverage of Neurocrine (NBIX) with an Overweight rating and a price target of $150, down from $185. The firm sees potential upside for Neurocrine shares with multiple commercial products, including Ingrezza and Crenessity, and late stage programs in schizophrenia and depression, the analyst tells investors.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NBIX:
- Positive Growth Outlook for Neurocrine Biosciences Driven by Ingrezza and Crenessity Sales Projections
- Neurocrine begins Phase 1 clinical study of NBI-1140675
- Positive Market Outlook for Neurocrine’s Crenessity Driven by Unmet Needs and Strong Physician Adoption
- Neurocrine reports patient-reported outcome data from KINECT-PRO study
- Neurocrine price target lowered to $183 from $191 at JPMorgan
Questions or Comments about the article? Write to editor@tipranks.com